Segantii Capital Management LTD I Mab Transaction History

Segantii Capital Management LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 21, 2022	SELL	$45.28 - $74.5 $6.34 Million - $10.4 Million	-140,000 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$57.18 - $84.43 $18 Million - $26.6 Million	-315,000 Reduced 69.23%	140,000 $10.1 Million
Q2 2021 Aug 06, 2021	BUY	$47.86 - $83.95 $12.2 Million - $21.4 Million	255,000 Added 127.5%	455,000 $38.2 Million
Q1 2021 May 11, 2021	BUY	$44.38 - $63.97 $8.88 Million - $12.8 Million	200,000 New	200,000 $9.69 Million

16.4M

1.9K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $108M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Segantii Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Segantii Capital Management LTD with notifications on news.